Story thread · 5 reports / 2 sources
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)
buffalonews.com · 21h
Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760 million outlook three months earlier. Levi & Korsinsky is investigating potential securities law violations.
First report: LegalZoom (LZ) Integrates Microsoft Copilot Amid Growth Shifts — finance.yahoo.com, 3d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.